127 related articles for article (PubMed ID: 30265649)
21. In vivo evaluation of anticancer efficacy of drug loaded cockle shell-derived aragonite nanoparticles.
Wenliang F; Rameli MABP; Ibrahim TAT; Noor MHM; Yusof LM; Zakaria MZAB
J Biomed Mater Res B Appl Biomater; 2019 Aug; 107(6):1898-1907. PubMed ID: 30597760
[TBL] [Abstract][Full Text] [Related]
22. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
[TBL] [Abstract][Full Text] [Related]
23. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
24. Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines.
Page RL; Hughes CS; Huyan S; Sagris J; Trogdon M
Anticancer Res; 2000; 20(5B):3533-8. PubMed ID: 11131658
[TBL] [Abstract][Full Text] [Related]
25. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling.
Hu T; Fei Z; Su H; Xie R; Chen L
Toxicol Appl Pharmacol; 2019 May; 371():55-62. PubMed ID: 30974157
[TBL] [Abstract][Full Text] [Related]
26. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
27. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
Lin BC; Huang D; Yu CQ; Mou Y; Liu YH; Zhang DW; Shi FJ
Med Sci Monit; 2016 May; 22():1761-5. PubMed ID: 27222034
[TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
30. Autophagy prevents doxorubicin‑induced apoptosis in osteosarcoma.
Zhao D; Yuan H; Yi F; Meng C; Zhu Q
Mol Med Rep; 2014 May; 9(5):1975-81. PubMed ID: 24639013
[TBL] [Abstract][Full Text] [Related]
31. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
Xia YZ; Ni K; Guo C; Zhang C; Geng YD; Wang ZD; Yang L; Kong LY
Phytomedicine; 2015 Mar; 22(3):344-51. PubMed ID: 25837271
[TBL] [Abstract][Full Text] [Related]
32. Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition.
Rouibah H; Kebsa W; Lahouel M; Zihlif M; Ahram M; Aburmeleih B; Mustafa E; Al-Ameer HJ
Anticancer Agents Med Chem; 2018; 18(3):375-387. PubMed ID: 29318976
[TBL] [Abstract][Full Text] [Related]
33. Naringin targets Zeb1 to suppress osteosarcoma cell proliferation and metastasis.
Ming H; Chuang Q; Jiashi W; Bin L; Guangbin W; Xianglu J
Aging (Albany NY); 2018 Dec; 10(12):4141-4151. PubMed ID: 30580326
[TBL] [Abstract][Full Text] [Related]
34. CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1.
Luo H; Zhou Z; Huang S; Ma M; Zhao M; Tang L; Quan Y; Zeng Y; Su L; Kim J; Zhang P
Cell Death Dis; 2021 Aug; 12(9):820. PubMed ID: 34462429
[TBL] [Abstract][Full Text] [Related]
35. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.
Rathore K; Cekanova M
Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087
[TBL] [Abstract][Full Text] [Related]
36. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
37. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies.
Gomes CM; van Paassen H; Romeo S; Welling MM; Feitsma RI; Abrunhosa AJ; Botelho MF; Hogendoorn PC; Pauwels E; Cleton-Jansen AM
Nucl Med Biol; 2006 Oct; 33(7):831-40. PubMed ID: 17045162
[TBL] [Abstract][Full Text] [Related]
38. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
[TBL] [Abstract][Full Text] [Related]
39. Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Feng T; Qiao G; Feng L; Qi W; Huang Y; Yao Y; Shen Z
Mol Med Rep; 2014 Dec; 10(6):2985-92. PubMed ID: 25310700
[TBL] [Abstract][Full Text] [Related]
40. [Sensitivity of doxorubicin-resistant osteosarcoma cells to doxorubicin regulated by long non-coding RNA NR_036444].
Zhu KP; Zhang CL
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):250-255. PubMed ID: 28550663
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
